Express Pharma

APRIL 17, 2023

Prometheus is a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialisation of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases. The acquisition is subject to Prometheus Biosciences shareholder approval.

Immunity 81

Immunity Immunization Research Laboratories Labelling 81

European Pharmaceutical Review

DECEMBER 15, 2023

When administered in the body, the RNA-encoded neoantigen sequences are endogenously translated and undergo natural cellular antigen processing and presentation, a key step in adaptive immunity. Keytruda is an immunotherapy that works by increasing the ability of the body’s immune system to help detect and fight tumour cells.

Vaccines 92

Vaccines Research Laboratories Immunity Immunization 92

Pharmaceutical Technology

OCTOBER 14, 2022

The mRNA-4157/V940 has been designed to stimulate an immune response by producing T-cell responses depending on the mutational signature of a patient's tumour.

Vaccines 115

Vaccines Research Laboratories Immunity Immunization 115

European Pharmaceutical Review

APRIL 17, 2023

I look forward to working with the Prometheus team to establish a new paradigm of precision treatment for immune diseases,” commented Dr Dean Y Li, President of Merck Research Laboratories. Prometheus is a clinical-stage biotechnology company. “I

Research Laboratories 87

Research Laboratories Immunity Immunization 87

Pharmaceutical Technology

JUNE 23, 2022

According to findings from a pivotal study, a four-dose paediatric regimen of Vaxneuvance induced immune responses non-inferior to the presently available 13-valent pneumococcal conjugate vaccine (PCV13) for the 13 shared serotypes.

Vaccines 59

Vaccines Research Laboratories Immunity Immunization 59

pharmaphorum

OCTOBER 14, 2021

Some cancer cells contain large amounts of PD-L1, which helps them to evade the body’s immune system. Dr Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories, said the data showing a 36% reduction in the risk of death “are compelling”.

Chemotherapy 45

Chemotherapy Research Laboratories Immunity Immunization 45

Pharmaceutical Technology

SEPTEMBER 28, 2022

An anti-programmed death receptor-1 (PD-1) therapy, Keytruda acts by boosting the immune system’s ability to find and fight tumour cells. With the latest development, the antibody is indicated for 23 usages in 13 different cancer types of cancer in the country.

Chemotherapy 59

Chemotherapy Research Laboratories Immunity Immunization 59